…
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -95.64M | -54.85M | -19.95M | -5.16M | -5.10M |
| Net income | -87.26M | -54.37M | -18.63M | -4.70M | -5.10M |
| Selling general administrative | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Reconciled depreciation | 0.84M | 0.48M | - | - | - |
| Ebit | -104.02M | -64.02M | -20.00M | -5.45M | -5.01M |
| Ebitda | -78.86M | -55.19M | -18.67M | -4.74M | -5.09M |
| Depreciation and amortization | 25.16M | 8.84M | 1.32M | 0.70M | -0.08M |
| Non operating income net other | 3.22M | 0.33M | -1.28M | - | - |
| Operating income | -104.02M | -64.02M | -20.00M | -5.45M | -5.01M |
| Other operating expenses | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Interest expense | 24.32M | 0.00M | 0.37M | 0.35M | 0.01M |
| Interest income | - | 0.34M | 0.12M | 0.05M | 0.09M |
| Net interest income | - | 0.33M | -0.24M | -0.29M | 0.08M |
| Non recurring | -10.00M | - | - | - | - |
| Income tax expense | -8.38M | -0.48M | -1.32M | -0.46M | -0.08M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Total other income expense net | 8.38M | 9.17M | 0.04M | 0.29M | -0.16M |
| Net income from continuing ops | -100.80M | -54.85M | -19.95M | -5.16M | -5.10M |
| Net income applicable to common shares | -95.64M | -54.85M | -19.99M | -5.16M | -5.10M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 160.25M | 258.15M | 332.01M | 279.56M | 2.19M |
| Other current assets | 5.68M | 7.19M | 7.04M | 7.66M | 0.10M |
| Total liab | 30.06M | 23.02M | 10.92M | 5.28M | 21.91M |
| Total stockholder equity | 130.19M | 235.14M | 321.08M | 274.28M | -19.72M |
| Other current liab | 28.71M | 18.60M | 8.44M | 3.12M | 0.85M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -309.21M | -191.53M | -95.89M | -41.04M | -21.09M |
| Other liab | - | - | - | - | 2.04M |
| Other assets | 0.00M | 0.47M | 5.27M | 84.58M | 0.03M |
| Cash | 90.58M | 95.97M | 110.54M | 60.62M | 2.06M |
| Total current liabilities | 28.84M | 21.43M | 9.29M | 4.41M | 1.27M |
| Current deferred revenue | -0.37M | - | - | - | - |
| Net debt | -89.00M | -94.06M | -108.62M | -59.62M | -0.50M |
| Short term debt | 0.37M | 0.33M | 0.29M | 0.12M | - |
| Short long term debt total | 1.58M | 1.91M | 1.92M | 1.00M | 1.55M |
| Other stockholder equity | 439.39M | 428.62M | 417.36M | 35.73M | 1.36M |
| Property plant equipment | - | 4.05M | 3.76M | 3.58M | - |
| Total current assets | 154.73M | 207.53M | 260.80M | 192.34M | 2.16M |
| Long term investments | 0.00M | 44.83M | 65.94M | 83.51M | - |
| Net tangible assets | - | 235.14M | 321.08M | 274.28M | -19.72M |
| Short term investments | 56.84M | 104.38M | 143.22M | 124.06M | 0.00M |
| Net receivables | 1.63M | 1.23M | 2.34M | 1.30M | 0.01M |
| Long term debt | - | - | - | - | 1.55M |
| Inventory | - | -1.23M | -2.34M | -1.30M | - |
| Accounts payable | 0.13M | 2.50M | 0.57M | 1.16M | 0.42M |
| Accumulated other comprehensive income | -0.35M | -1.96M | -0.39M | 0.03M | - |
| Common stock total equity | - | 0.00M | 0.00M | 0.00M | - |
| Retained earnings total equity | - | -191.53M | -95.89M | -41.04M | - |
| Non currrent assets other | 0.45M | 0.47M | 0.06M | 0.13M | 0.03M |
| Non current assets total | 5.52M | 50.62M | 71.21M | 87.23M | 0.03M |
| Capital lease obligations | 1.58M | 1.91M | 1.92M | 1.00M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 58.80M | -2.51M | -210.07M | 1.50M | 2.00M |
| Change to liabilities | 2.10M | 5.15M | 1.10M | 0.70M | 0.29M |
| Total cashflows from investing activities | 57.66M | -4.08M | -210.07M | 1.51M | 2.01M |
| Net borrowings | - | - | 1.66M | 0.87M | 1.27M |
| Total cash from financing activities | 0.65M | 97.09M | 292.75M | 0.95M | 1.46M |
| Change to operating activities | 8.73M | 2.05M | 0.06M | 0.06M | -0.05M |
| Net income | -95.64M | -54.85M | -19.95M | -5.16M | -5.10M |
| Change in cash | -14.15M | 49.91M | 58.57M | -1.26M | -1.01M |
| Begin period cash flow | 110.54M | 60.62M | 2.06M | 3.32M | 4.33M |
| End period cash flow | 96.39M | 110.54M | 60.62M | 2.06M | 3.32M |
| Total cash from operating activities | -72.47M | -43.10M | -24.11M | -3.71M | -4.48M |
| Issuance of capital stock | 0.00M | 96.76M | 290.44M | 0.00M | 0.10M |
| Depreciation | 0.84M | 0.48M | 0.25M | 0.00M | 0.00M |
| Other cashflows from investing activities | - | - | 0.04M | 0.01M | 0.01M |
| Change to account receivables | 1.11M | -1.04M | -7.61M | -0.02M | -0.02M |
| Sale purchase of stock | - | 96.76M | 208.52M | - | - |
| Other cashflows from financing activities | 57.66M | 0.33M | 84.23M | 0.95M | 1.46M |
| Change to netincome | 10.61M | 4.62M | 2.00M | 0.51M | 0.36M |
| Capital expenditures | 1.14M | 1.57M | 2.32M | 2.32M | 2.32M |
| Cash flows other operating | 10.04M | 1.01M | -7.94M | - | - |
| Cash and cash equivalents changes | -14.15M | 49.91M | 58.57M | - | - |
| Change in working capital | 11.94M | 6.16M | -6.45M | 0.68M | 0.24M |
| Stock based compensation | 10.61M | 4.62M | 0.63M | 0.25M | 0.20M |
| Other non cash items | -0.22M | 0.49M | 1.65M | 0.52M | 0.17M |
| Free cash flow | -73.61M | -44.67M | -26.43M | -3.71M | -4.48M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-1.21 2.90% |
40.40 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.15 1.14% |
531.64 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.70 0.49% |
957.10 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark J. Litton M.B.A., MBA, Ph.D. | Pres, CEO & Director | 1968 |
| Ms. Rachel P. Lenington M.B.A. | Chief Operating Officer | NA |
| Mr. Mark F. Worthington J.D. | Gen. Counsel & Corp. Sec. | NA |
| Ms. Glenna K. Mileson | Chief Financial Officer | 1959 |
| Mr. Robert Renninger | Director of Accounting & Reporting | NA |
| Ms. Julie Rathbun | Head of Investor Relations | NA |
| Dr. Kevin Church Ph.D. | Exec. VP of Research | 1985 |
| Dr. Mark J. Litton M.B.A., Ph.D. | President, CEO & Director | 1968 |
| Ms. Rachel P. Lenington M.B.A. | Chief Development Officer & COO | 1973 |
| Mr. Andrew W. Gengos | CFO & Chief Business Officer | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.